SynthesisCancer control : journal of the Moffitt Cancer Center
The Efficacy and Safety of Anlotinib Combination Therapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionAnlotinib, a tyrosine kinase inhibitor, has demonstrated significant anti-tumor activity in hepatocellular carcinoma (HCC); nevertheless, the optimal combination therapy is still contested. Consequently, we synthesized the efficacy and safety of anlotinib in combination therapy for advanced HCC via meta-analysis, offering more extensive data for clinical application.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library. The primary efficacy indicators included median overall survival (mOS), median progression-free survival (mPFS), overall response rate (ORR), and disease control rate (DCR). The relevant safety indicators were adverse events (AEs). We conducted a meta-analysis utilizing the STATA 14.0 statistical software.ResultsA total of 14 studies involving 863 patients with HCC were included. The combination therapy with anlotinib showed an ORR of 33.8% (95% confidence intervals (CI): 26.8%-40.7%) and a DCR of 77.1% (95% CI: 70.1%-84.2%). The mPFS and mOS were 6.9 months (95% CI: 6.2-7.6) and 17.1 months (95% CI: 15.6-18.6), respectively. Common AEs associated with anlotinib combination therapy included liver function abnormalities 52.9% (95% CI: 37.7%-68.0%), hand-foot skin reaction 37.2% (95% CI: 26.2%-48.2%), and decreased appetite 32.0% (95% CI: 18.7%-45.3%).ConclusionsAnlotinib-based combination therapy demonstrated promising efficacy with manageable safety in advanced HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.